Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
306 participants
OBSERVATIONAL
2020-07-22
2022-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System
NCT01514292
Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
NCT03566693
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
NCT03620357
Glucose Risk Assessment in Employer Populations
NCT04529824
Diabetes Education With Real-time Continuous Glucose Monitoring
NCT05394844
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Sleep
* Exercise/Physical activity/or lack of it
* Heart rate
* Five hours OGTT- 6 subjects in each group that have C-Peptide positive lab result at screening and consent to the OGTT (Appendix 3) This data will address the sources and nature of blood glucose variability across the progression of PD and T2D. The data collected in this study will enable investigation into CGM-data artifacts that speak to the state and management of PD and T2D. Possible applications enabled by these data sets include: compliance with drug regimens and other lifestyle recommendations, drug titration and/or escalation/de-escalation, and diagnosis and/or treatment throughout the progression of the disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prediabetes (both IGT and IFG)
Device: G6 Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
G6
Wear 9 wear periods of the 10-day CGM
Type 2 Diabetes on 1 OAD
Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
G6
Wear 9 wear periods of the 10-day CGM
Type 2 Diabetes on 2 or more OAD
Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
G6
Wear 9 wear periods of the 10-day CGM
Type 2 Diabetes using Basal insulin with or without OAD
Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
G6
Wear 9 wear periods of the 10-day CGM
Type 2 Diabetes in GLP-1 with or without OAD
Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
G6
Wear 9 wear periods of the 10-day CGM
Type 2 Diabetes using intense insulin treatment-Multiple Dail
Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
G6
Wear 9 wear periods of the 10-day CGM
Type 2 Diabetes in MDI or basal insulin plus GLP-1
Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
G6
Wear 9 wear periods of the 10-day CGM
Type 2 Diabetes on 0 OAD
Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
G6
Wear 9 wear periods of the 10-day CGM
High Risk to Develop Prediabetes / Type 2 Diabetes
Participant to wear G6 and activity tracker for 3 months and add meals and medications into e-diary daily
G6
Wear 9 wear periods of the 10-day CGM
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
G6
Wear 9 wear periods of the 10-day CGM
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High Risk of developing PD or T2D with HbA1c ≤5.6%
With one or more of the following:
* Strong family history of T2D
* BMI ≥35 kg/m2
* History of gestational diabetes mellitus (GDM)
* Age and Race, Ethnicity
* Polycistic Ovarian Syndrome
* High Blood Pressure
* Abnormal cholesterol and triglyceride levels
* Clinical Diagnosis of Prediabetes (PD) as defined by ADA to have an HbA1c ≥5.7%-6.4%. or clinical diagnosis of Type 2 Diabetes (T2D) with HbA1c between ≥6.5 % and ≤12.0%. Determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
* Having no treatment, one or more of the combination of treatments for the disease in every spectrum such as exercise and diet for PD and no treatment, 1 or more methods of treatment for T2D and combination of treatments for the disease MDI or CSII alone, MDI or CSII plus OAD and MDI or CSII with or without GLP-1 with or without OAD.
* No change in diabetic medication in the last three months for patients in treatment.
* Willingness to use a study provided CGM, use of an activity tracker, and agree to record data related to food and medication intake in an e-diary (e.g. mobile app).
* For a subset of subjects who agree to provide consent, an OGTT will be performed as explained on Appendix 3. OGTT will be performed on 6 subjects per group that have a lab result with positive c-peptide. Having a smartphone compatible with Dexcom G6 CGM, activity tracker \& e-Diary. (This could be provided by the study team if the qualified subject does not have smartphone compatible with apps. For users that do not use their personal smartphones for data collection purposes, the T2Help study will provide a commercially available smartphone. The smartphones will be modified so they are only capable of hosting and running the study applications required for data collection (Fitbit, Welldoc, G6). The modified smartphones will not be able to execute standard smartphone functionality such as internet browsing, texting, or making phone calls. Bluetooth functionality will remain intact as it is required for the approved applications to collect data.)
* If using additional medication, such as thyroid, hypertension, and cholesterol lowering medication these have to be stable for at least 3 months.
Exclusion Criteria
* History of 2 or more episodes of severe hypoglycemia, which resulted in any of the following during the 6 months prior to screening:
Medical assistance by a third party (Caregiver needed to inject glucagon, ER visit, hospitalization) Coma Seizures
* Subject has a skin condition for which he/she is unable to tolerate tape adhesive in the area of sensor placement.
* Pregnancy (as demonstrated by a positive test at study entry) at time of screening or are planning to become pregnant during the study.
* Subject has had any of the following cardiovascular events within 3 months of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, recent transient ischemic attack, cerebrovascular accident with sequelae, unstable angina, unstable congestive heart failure, unstable ventricular rhythm disturbances or thromboembolic disease.
* Unstable thyroid disease. (changes in Thyroid medication in the last 90 days)
* Subject has taken any oral, injectable, or intravenous (IV) steroids within 8 weeks from the time of screening visit, or plans to take any oral, injectable, or IV steroids during the course of the study.
* Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks.
* Subject is currently using illicit drugs.
* Subject is currently abusing prescription drugs.
* Subject is currently abusing alcohol.
* Subject has a history of visual impairment which would not allow him/her to participate in the study and perform all study procedures safely, as determined by the investigator.
* Subject has elective surgery planned that requires general anesthesia during the course of the study.
* Subject has a sickle cell disease, hemoglobinopathy, or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening.
* Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation.
* Subject diagnosed with current eating disorder such as anorexia or bulimia.
* Subject is on dialysis.
* Subject has eGFR \<45 confirmed by medical record.
* Recent Pancreatitis. (\< 30 days)
* Cancer/malignancy in treatment.
* Cystic fibrosis.
* Any other problem for which the investigator or the sponsor may believe that the subject will not be able to comply with the study. (e.g. use of hydroxyurea)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DexCom, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Danny Chernavvsky, MD
Role: STUDY_DIRECTOR
DexCom, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Synergy San Diego
Lemon Grove, California, United States
Palm Research Center
Las Vegas, Nevada, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Oregon Health & Science University
Portland, Oregon, United States
Diabetes and Glandular Disease
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PTL-904050
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.